ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2128

Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics

Iain B McInnes1, John Tesser2, Elena Schiopu3, Joseph Merola4, Soumya Chakravarty5, Emmanouil Rampakakis6, Natalie Shiff7, Alexa Kollmeier8, Xie L Xu9, May Shawi10, Frederic Lavie11, Paul Bird12 and Philip J Mease13, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 3Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, 8Janssen-Cilag, Research & Development, LLC, San Diego, CA, 9Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, 10Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 11The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, Paris, France, 12University of New South Wales, Sydney, Australia, 13Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

Meeting: ACR Convergence 2022

Keywords: Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster III: PsA

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: In the phase 3 DISCOVER (D)-1 and D-2 studies, guselkumab (GUS) significantly improved joint symptoms, skin disease, enthesitis, dactylitis, physical function, and quality of life at Week (W)24 in patients (pts) with psoriatic arthritis (PsA).1,2 Clinical responses across these disease domains were maintained or increased with GUS at W52,3,4 regardless of baseline (BL) pt demographics, disease characteristics, or conventional synthetic disease-modifying antirheumatic drug (csDMARD) use.5 Durable efficacy with GUS through W100 across multiple disease domains was observed.6 This study assessed both BL predictors of, and by BL pt subgroups, GUS efficacy across PsA disease domains through W100 of D-2.

Methods: Biologic-naïve pts with active PsA despite standard therapies in D-2 (swollen joint count [SJC] ≥5 & tender joint count [TJC] ≥5, C-reactive protein [CRP] ≥0.6 mg/dL) were randomized 1:1:1 to GUS 100 mg every 4 weeks (Q4W); GUS 100 mg at W0, W4, then Q8W; or placebo (PBO).2 GUS effects on joint, skin, enthesitis, dactylitis, spinal pain, and disease severity endpoints (change in Disease Activity in PsA [DAPSA], SJC, and TJC scores; Psoriasis [PsO] Area Severity Index [PASI] score [among pts with BL IGA ≥2 and body surface area [BSA] with PsO ≥3%]; Leeds enthesitis index [LEI] score; dactylitis score; spinal pain score; and PsA Disease Activity Score [PASDAS], respectively) at W100 were evaluated for GUS-randomized pts. A multivariate linear model adjusting for BL pt characteristics assessed associations between BL predictors and changes in DAPSA, PASI, and LEI scores from BL to W100, and least squares mean changes and 95% confidence intervals in all continuous endpoints from BL to W100 within subgroups of pts defined by BL sex, body mass index, PsA duration, SJC, TJC, CRP, %BSA, PASI score, and csDMARD use.

Results: 442 (90%) GUS-randomized pts completed study treatment through W100.6 Among the BL predictors of long-term GUS efficacy assessed, only PsA duration (p=0.032), SJC (p< 0.001), and TJC (p< 0.001) were significant predictors of long-term (BL to W100) DAPSA score change; %BSA (p=0.002), PASI score (p< 0.001), SJC (p=0.008), and csDMARD use (p=0.014) were significant predictors of long-term PASI score change; and none significantly predicted long-term LEI score change among pooled GUS pts (Fig). However, statistically significant improvements from BL to W100 in DAPSA, PASI, and LEI scores were observed across all BL strata in pooled GUS Q4W+Q8W pts (Fig, all p< 0.001) and within each dosing group. Similar improvements were observed for other continuous endpoints assessed (change in PASDAS, SJC, TJC, spinal pain, and dactylitis score).

Conclusion: GUS significantly improved PsA signs and symptoms through W100 across all BL pt subgroups including pts with highly active disease regardless of dosing regimen.

References:
1. Deodhar A et al. Lancet 2020; 395:1115-25
2. Mease PJ et al. Lancet 2020; 395;1126-36
3. Ritchlin CT et al. RMD Open 2021;7(1):e001457
4. McInnes IB et al. Arthritis Rheumatol 2021; 73:604-16
5. Ritchlin CT et al. Ann Rheum Dis 2021; 80:1291-2
6. McInnes IB et al. Arthritis Rheumatol 2021; doi: 10.1002/art.42010

Supporting image 1


Disclosures: I. McInnes, Bristol-Myers Squibb (BMS), Janssen, Novartis, UCB, Pfizer, AbbVie, Celgene, AstraZeneca, Boehringer Ingelheim, EveloBio, LEO, Lilly; J. Tesser, AbbVie, Amgen, Bristol-Myers Squibb(BMS), Celgene, CoreVitas, Eli Lilly, Gilead, Janssen, Pfizer, Sun Pharma, Novartis; E. Schiopu, Janssen; J. Merola, Novartis, Pfizer, Sun Pharma, UCB Pharma, Bristol-Myers Squibb(BMS), AbbVie, Dermavant, Eli Lilly, Janssen, Arena, Biogen; S. Chakravarty, Janssen Scientific Affairs, LLC, Johnson & Johnson; E. Rampakakis, Janssen, JSS Medical Research; N. Shiff, AbbVie/Abbott, Gilead, Johnson & Johnson, Janssen Scientific Affairs, LLC; A. Kollmeier, Janssen Research & Development, LLC, Johnson & Johnson; X. Xu, Janssen Research & Development, LLC, Johnson & Johnson; M. Shawi, Janssen Pharmaceutical Companies of Johnson and Johnson; F. Lavie, Janssen; P. Bird, AbbVie/Abbott, Eli Lilly, Gilead, Janssen, Merck/MSD, Pfizer, UCB, Novartis; P. Mease, AbbVie, Amgen, Janssen, Novartis, Pfizer Inc, UCB, Sun Pharma, Eli Lilly, Bristol-Myers Squibb(BMS), Celgene, Genentech.

To cite this abstract in AMA style:

McInnes I, Tesser J, Schiopu E, Merola J, Chakravarty S, Rampakakis E, Shiff N, Kollmeier A, Xu X, Shawi M, Lavie F, Bird P, Mease P. Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/consistent-long-term-guselkumab-efficacy-across-psoriatic-arthritis-domains-irrespective-of-baseline-patient-characteristics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/consistent-long-term-guselkumab-efficacy-across-psoriatic-arthritis-domains-irrespective-of-baseline-patient-characteristics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology